Rizatriptan: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Rizatriptan. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Neurological | 20% |
| Digestive | 13% |
| Pain and other pressure sensations | 9% |
| Dizziness | 9% |
| Somnolence | 8% |
| Asthenia/fatigue | 7% |
| Nausea | 6% |
| Atypical sensations | 5% |
| Paresthesia | 4% |
| Tightness/pressure and/or heaviness | 3% |
| Pain, location unspecified | 3% |
| Dry mouth | 3% |
| Pain/tightness/pressure | 2% |
| Tightness/pressure/heaviness | 2% |
| Headache | 2% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
MAXALT is indicated for the acute treatment of migraine attacks with or without aura in adults. MAXALT is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of MAXALT have not been established for cluster headache, which is present in an older, predominantly male population.
Source: FDA labeling via NIH DailyMed (set 08d06e6f…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.